Mesters R - Search Results

1

Nanoparticles that communicate in vivo to amplify tumour targeting.

von Maltzahn G, Park JH, Lin KY, Singh N, Schwöppe C, Mesters R, Berdel WE, Ruoslahti E, Sailor MJ, Bhatia SN. von Maltzahn G, et al. Among authors: mesters r. Nat Mater. 2011 Jun 19;10(7):545-52. doi: 10.1038/nmat3049. Nat Mater. 2011. PMID: 21685903 Free PMC article.

2

Interleukin 8 and Flt3 ligand as markers of advanced disease in primary gastrointestinal non-Hodgkin's lymphoma.

Retzlaff S, Padró T, Koch P, Oelmann E, Lügering N, Mesters RM, Berdel WE. Retzlaff S, et al. Oncol Rep. 2002 May-Jun;9(3):525-7. Oncol Rep. 2002. PMID: 11956621

3

Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma.

Bieker R, Kessler T, Berdel WE, Mesters RM. Bieker R, et al. Among authors: mesters rm. Oncol Rep. 2003 Nov-Dec;10(6):1915-7. doi: 10.3892/or.10.6.1915. Oncol Rep. 2003. PMID: 14534718

4

Signal transduction pathways as novel therapy targets in lung cancer.

Reinmuth N, Mesters RM, Bieker R, Hoffknecht P, Berdel WE, Thomas M. Reinmuth N, et al. Among authors: mesters rm. Lung Cancer. 2004 Aug;45 Suppl 2:S177-86. doi: 10.1016/j.lungcan.2004.07.976. Lung Cancer. 2004. PMID: 15552798 Review.

5

Prognostic relevance of increased angiogenesis in osteosarcoma.

Kreuter M, Bieker R, Bielack SS, Auras T, Buerger H, Gosheger G, Jurgens H, Berdel WE, Mesters RM. Kreuter M, et al. Among authors: mesters rm. Clin Cancer Res. 2004 Dec 15;10(24):8531-7. doi: 10.1158/1078-0432.CCR-04-0969. Clin Cancer Res. 2004. PMID: 15623635

6

Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.

Kessler T, Bieker R, Padró T, Schwöppe C, Persigehl T, Bremer C, Kreuter M, Berdel WE, Mesters RM. Kessler T, et al. Among authors: mesters rm. Clin Cancer Res. 2005 Sep 1;11(17):6317-24. doi: 10.1158/1078-0432.CCR-05-0389. Clin Cancer Res. 2005. PMID: 16144936

7

Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer.

Reinmuth N, Piegelbrock E, Raedel M, Fehrmann N, Hintelmann H, Wagner R, Berdel WE, Thomas M, Freitag L, Mesters RM. Reinmuth N, et al. Among authors: mesters rm. Lung Cancer. 2007 Jan;55(1):53-60. doi: 10.1016/j.lungcan.2006.09.025. Epub 2006 Oct 25. Lung Cancer. 2007. PMID: 17067717

8

Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies.

Kessler T, Fehrmann F, Bieker R, Berdel WE, Mesters RM. Kessler T, et al. Among authors: mesters rm. Curr Drug Targets. 2007 Feb;8(2):257-68. doi: 10.2174/138945007779940089. Curr Drug Targets. 2007. PMID: 17305503 Review.

9

New molecular therapy targets in acute myeloid leukemia.

Krug U, Serve H, Müller-Tidow C, Mesters RM, Steffen B, Büchner T, Berdel WE. Krug U, et al. Recent Results Cancer Res. 2007;176:243-62. doi: 10.1007/978-3-540-46091-6_21. Recent Results Cancer Res. 2007. PMID: 17607931 Review.

10

Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.

Reinmuth N, Rensinghoff S, Raedel M, Fehrmann N, Schwöppe C, Kessler T, Bisping G, Hilberg F, Roth GJ, Berdel W, Thomas M, Mesters RM. Reinmuth N, et al. Int J Oncol. 2007 Sep;31(3):621-6. Int J Oncol. 2007. PMID: 17671690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

174 results

Search Page